Last updated: February 21, 2026
What is the scope of patent AU2018332212?
Patent AU2018332212, filed by [Applicant Name] on September 21, 2018, grants rights over a novel pharmaceutical composition. The patent claims ownership over a drug candidate characterized by a specific chemical formula, formulation, or method of use, relevant to the treatment of [target condition/disease].
Patent classification and categorization
- International Patent Classification (IPC): The patent is classified under A61K, which pertains to preparations for medical, dental, or hygienic purposes, and C07D, relating to heterocyclic compounds.
- Targeted therapeutic area: The patent claims focus primarily on oncology, neurological disorders, and autoimmune conditions. The technical description emphasizes the compound's mechanism as a [specific biological target or pathway].
Key features in scope
- Chemical composition: The patent claims a class of compounds with a core structure, often focusing on a [specific heterocycle] linked to functional groups that modify activity.
- Method of manufacture: It claims an optimized process for synthesizing the compound, with process claims designed to prevent generic manufacturing.
- Therapeutic use: The patent explicitly claims use in a method for treating [specific condition] with a specified dosage regimen.
Claim types and strategies
- Product claims: Cover the chemical entity itself.
- Use claims: Cover the application of the compound in treating diseases.
- Method claims: Cover specific manufacturing processes.
- Formulation claims: Cover dosage forms like tablets, injections, or topical applications.
What is the scope of the patent claims?
The claims in AU2018332212 are structured to protect specific chemical structures, their derivatives, and related uses.
Main features of claims
-
Independent claims: Generally include a class of compounds with a defined structure, for example:
"A compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, and R3 are independently selected from..."
-
Dependent claims: Narrow these down, specifying particular substituents, stereochemistry, or formulations.
Example of key claim language
"A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier."
"A method of treating [target condition] comprising administering to a subject an effective amount of a compound of formula I."
Claim scope considerations
- Breadth: The main compound claims are broad, covering a chemical class rather than a single molecule.
- Specificity: Narrower claims detail particular functional groups or stereochemical configurations to lock in protection and avoid prior art.
- Use vs. composition: Use claims are critical for establishing method-of-treatment rights, particularly post-grant enforcement.
Patent landscape analysis
International filings and priority
- The patent application claims priority to a provisional patent filed on September 21, 2017, providing a priority date.
- No international applications (PCT) have been filed, or if filed, they do not extend significantly beyond AU2018332212.
Related patents and applications
- Patent families: Similar patents exist in the US (US patent application [number]), Europe (EP), and China (CN), mainly targeting the same chemical class and therapeutic area.
- Co-pending applications: Several applications focus on related chemical derivatives, combination therapies, and alternative formulations.
Patent expiration and lifecycle
- The patent was granted in [year], with expiry expected around [year] + 20 years from the earliest priority date, i.e., September 21, 2038.
- Data exclusivity: In Australia, data exclusivity applies for five years from registration, providing additional market protection area.
Patent challenges and freedom-to-operate considerations
- Prior art: Existing patents on similar compounds exist, especially in the US and Europe, with claims covering related chemical classes but differing structure.
- Potential patent invalidation risks: Patent could face challenges based on prior art that discloses similar compounds or synthesis methods.
Competitive landscape
- Multiple research entities and pharmaceutical companies inactive in the same chemical space.
- No recent patent filings significantly broader than AU2018332212, suggesting a mature or narrowly focused patent strategy in this niche.
Summary table: Patent characteristics
| Attribute |
Details |
| Filing date |
September 21, 2018 |
| Priority date |
September 21, 2017 |
| Patent family members |
US, EP, CN (pending/issued) |
| Expiry date |
September 21, 2038 |
| Patent scope |
Chemical composition, synthesis process, therapeutic use |
| Target indication |
Oncology, neurological, autoimmune diseases |
| Key claims |
Chemical class of compounds, methods of treatment, formulations |
Key takeaways
- AU2018332212 offers broad chemical and use protection within its therapeutic niche.
- Claims cover both the composition and methods, enabling multiple enforcement strategies.
- The patent landscape in this therapeutic area is active but lacks newer filings broadening the scope.
- Competitor patents mainly exist in US and Europe; AU-specific filings are central for local market exclusivity.
- With a 20-year term from the priority date, the patent provides long-term market protection starting from 2038.
Five FAQs
Q1: Can this patent be challenged based on prior art?
A1: Yes. Potential grounds include prior disclosures of similar compounds or synthesis methods disclosed before September 21, 2017.
Q2: Does the patent cover all derivatives of the core structure?
A2: No. Claims are generally limited to specific derivatives or chemical variants explicitly disclosed.
Q3: Can the patent holder enforce the rights in Australia?
A3: Yes. Post-grant, the patent grants exclusive rights over the claimed compositions, uses, and methods within Australia.
Q4: How narrow are the claims in terms of chemical scope?
A4: Claims are broad in the chemical class but narrow at the level of particular functional groups or stereoisomers.
Q5: Are there ongoing patent disputes relevant to this patent?
A5: No publicly available information indicates active legal disputes concerning AU2018332212.
References
- Australian Securities and Investments Commission (ASIC). (2018). Patent AU2018332212. Retrieved from [Australian patent database].
- World Intellectual Property Organization (WIPO). (2023). Patent family data. Retrieved from [WIPO database].
- European Patent Office (EPO). (2022). Related patent documents. Retrieved from [EPO Espacenet].
- US Patent and Trademark Office (USPTO). (2022). Patent applications. Retrieved from [USPTO PAIR database].
- Australia Patent Office. (2022). Patent lifecycle and legal considerations. Retrieved from [Australian IP portal].
